Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer.  As a glucoCORticoid receptor antagonist, it is hard to pronounce.

Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

ICI-Induced T1DM

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.